Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study

Dupilumab, a human IL-4R- α mAb inhibiting IL-4 and IL-13, key drivers of type 2-mediated inflammation, is approved for uncontrolled moderate-to-severe atopic dermatitis in adults and in the USA for patients aged ≥12 years with moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. In a phase 2a study, d upilumab improved endoscopic, radiologic, clinical, and patient-reported outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) patients. For the first time we report results from a phase 3 dupilumab study (SINUS-24; NCT02912468) in severe CRSwNP patients (with/without comorbid asthma) on dai ly intra-nasal mometasone furoate (MFNS).

Source: Journal of Allergy and Clinical Immunology - February 1, 2019 Category: Allergy & Immunology Authors: Joseph K. Han, Claus Bachert, Martin Desrosiers, Tanya M. Laidlaw, Claire Hopkins, Wytske J. Fokkens, Pierluigi Paggiaro, Seong Ho Cho, Heidi Olze, Leon S. Greos, Mei Zhang, Chunpeng Fan, Steven Draikiwicz, Nikhil Amin, Siddhesh Kamat, Asif Khan, Gianluca Source Type: research